PTC Therapeutics Dirección

Dirección controles de criterios 3/4

PTC Therapeutics' El consejero delegado es Matt Klein , nombrado en Mar 2023, tiene un mandato de 1.08 años. la remuneración anual total es $5.01M , compuesta por 11.9% salario y 88.1% primas, incluidas acciones y opciones de la empresa. posee directamente 0.057% de las acciones de la empresa, por valor de $1.26M . La antigüedad media del equipo directivo y del consejo de administración es de 7.2 años y 8.8 años respectivamente.

Información clave

Matt Klein

Chief Executive Officer (CEO)

US$5.0m

Compensación total

Porcentaje del salario del CEO	11.9%
Permanencia del CEO	1.1yrs
Participación del CEO	0.06%
Permanencia media de la dirección	7.2yrs
Promedio de permanencia en la Junta Directiva	8.8yrs

Actualizaciones recientes de la dirección

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27

PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

Apr 11

Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?

Feb 09

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate

Dec 27

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Matt Klein en comparación con los beneficios de PTC Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$627m
Sep 30 2023	n/a	n/a	-US$642m
Jun 30 2023	n/a	n/a	-US$618m
Mar 31 2023	n/a	n/a	-US$571m
Dec 31 2022	US$5m	US$598k	-US$559m

Compensación vs. Mercado: La compensación total de Matt ($USD5.01M) es aproximadamente el promedio para empresas de tamaño similar en el mercado US ($USD5.11M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Matt con los resultados de la empresa.

CEO

Matt Klein (50 yo)

1.1yrs

Permanencia

US$5,009,299

Compensación

Dr. Matthew B. Klein, also known as Matt, M.D., MS, FACS, serves as Chief Executive Officer and Director of PTC Therapeutics, Inc. since March 24, 2023He served as an Independent Director at ClearPoint Neu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Matthew Klein	CEO & Director	1.1yrs	US$5.01m	0.057% $ 1.1m
Stuart Peltz	Co-Founder	26.3yrs	US$7.16m	0.097% $ 2.0m
Allan Jacobson	Co-Founder	26.3yrs	US$553.96k	0.016% $ 326.3k
Neil Almstead	Chief Technical Operations Officer	5.3yrs	US$2.67m	0.054% $ 1.1m
Eric Pauwels	Chief Business Officer	9yrs	US$2.99m	0.022% $ 455.2k
Pierre Gravier	Chief Financial Officer	less than a year	sin datos	0.010% $ 203.4k
Christine Utter	Senior VP	4.8yrs	US$1.70m	0.022% $ 450.5k
Alex Kane	Investor Relations Officer	no data	sin datos	sin datos
Mark Boulding	Executive VP & Chief Legal Officer	12.1yrs	US$4.29m	0.064% $ 1.3m
Jane Baj	Vice President of Corporate Communications	no data	sin datos	sin datos
Hege Sollie-Zetlmayer	Senior Vice President of Human Resources	3.5yrs	sin datos	sin datos
Murad Husain	Senior Vice President of Global Regulatory Affairs	9.3yrs	sin datos	sin datos

7.2yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: PTCTEl equipo directivo de la empresa es veterano y experimentado (6.8 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Matthew Klein	CEO & Director	1.1yrs	US$5.01m	0.057% $ 1.1m
Stuart Peltz	Co-Founder	1.1yrs	US$7.16m	0.097% $ 2.0m
Allan Jacobson	Co-Founder	26.3yrs	US$553.96k	0.016% $ 326.3k
Michael Schmertzler	Independent Chairman of the Board	22.7yrs	US$908.42k	1.96% $ 39.7m
David Southwell	Independent Director	18.3yrs	US$488.46k	0.0085% $ 171.6k
Eric Jacobsen	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Emma Reeve	Independent Director	5.3yrs	US$491.46k	0.0094% $ 190.3k
Joseph Puglisi	Member of Scientific Advisory Board	20.4yrs	sin datos	sin datos
Glenn Steele	Independent Director	8.8yrs	US$468.96k	0.0085% $ 171.6k
Marvin Wickens	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert Schneider	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephanie Okey	Independent Director	5.3yrs	US$463.96k	0.0077% $ 155.0k

8.8yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de PTCT se considera experimentada (8.8 años de antigüedad promedio).

PTC Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

Recent updates

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Price target decreased to US$51.46

Insufficient new directors

Price target decreased to US$52.31

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.

Executive VP & Chief Legal Officer exercised options and sold US$167k worth of stock

PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Executive VP & Chief Legal Officer notifies of intention to sell stock

Price target increased to US$54.64

Insider recently sold US$119k worth of stock

Consensus forecasts updated

PTC Therapeutics, Inc. Provides Key Clinical/Regulatory Updates

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2022

PTC Therapeutics, Inc. Announces Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

PTC Therapeutics, Inc. Appoints Alethia Young to its Board of Directors

PTC Therapeutics, Inc. Announces Preliminary Results Presented At ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

PTC Therapeutics, Inc. Announces FDA Approves Label Extension for Evrysdi for Infants with Spinal Muscular Atrophy Under 2 Months Old

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

PTC Therapeutics, Inc. Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency